1. Altered Basal Lipid Metabolism Underlies the Functional Impairment of Naive CD8 + T Cells in Elderly Humans.
- Author
-
Nicoli F, Cabral-Piccin MP, Papagno L, Gallerani E, Fusaro M, Folcher V, Dubois M, Clave E, Vallet H, Frere JJ, Gostick E, Llewellyn-Lacey S, Price DA, Toubert A, Dupré L, Boddaert J, Caputo A, Gavioli R, and Appay V
- Subjects
- Adult, Aged, Aged, 80 and over, Apoptosis, CD8-Positive T-Lymphocytes metabolism, COVID-19 immunology, Cancer Vaccines immunology, Cell Division, Female, Fenofibrate pharmacology, Glucose metabolism, HLA-A2 Antigen immunology, Humans, Hypolipidemic Agents pharmacology, Hypolipidemic Agents therapeutic use, Influenza, Human immunology, Lymphocyte Activation, MART-1 Antigen chemistry, MART-1 Antigen immunology, Male, Middle Aged, Neoplasms immunology, Peptide Fragments immunology, Rosiglitazone pharmacology, Single-Blind Method, Vaccination, Viral Vaccines immunology, Young Adult, Aging immunology, CD8-Positive T-Lymphocytes immunology, Immunocompetence drug effects, Lipid Metabolism drug effects
- Abstract
Aging is associated with functional deficits in the naive T cell compartment, which compromise the generation of de novo immune responses against previously unencountered Ags. The mechanisms that underlie this phenomenon have nonetheless remained unclear. We found that naive CD8
+ T cells in elderly humans were prone to apoptosis and proliferated suboptimally in response to stimulation via the TCR. These abnormalities were associated with dysregulated lipid metabolism under homeostatic conditions and enhanced levels of basal activation. Importantly, reversal of the bioenergetic anomalies with lipid-altering drugs, such as rosiglitazone, almost completely restored the Ag responsiveness of naive CD8+ T cells. Interventions that favor lipid catabolism may therefore find utility as adjunctive therapies in the elderly to promote vaccine-induced immunity against targetable cancers and emerging pathogens, such as seasonal influenza viruses and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)., (Copyright © 2022 by The American Association of Immunologists, Inc.)- Published
- 2022
- Full Text
- View/download PDF